Consider low-dose theophylline to reduce corticosteroid resistance, ... Tiotropium reduced COPD exacerbations, ... COPD study Azithromycin or placebo added to usual care COPD treatments: ...

Although there is a lack of robust clinical studies to support the recommendation of specific interventions for excessive mucus production in COPD, several therapies have been considered. 4 For ...

Medicare Part D or Original Medicare may cover azithromycin, depending on its form. ... such as chronic obstructive pulmonary disease (COPD) exacerbations, skin infections, and pharyngitis. ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study is published in the May 2025 issue of Chronic ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, breaks down how to communicate the value of ...

a Formal significance testing was only performed at 52 weeks in the Phase 3 trials, with significance achieved for both the every two-week arm and every four-week arm in AERIFY-1 . The total number of ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study published in Chronic Obstructive Pulmonary Diseases ...

Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe COPD characterized by an eosinophilic phenotype, according to ...

Azithromycin or placebo added to usual care COPD treatments 3 to prevent one exacerbation per year Exacerbations reduced despite development of antibiotic resistancen = 1142 ...

A total of 2,802 patients with COPD were randomised 1:1 to receive FF/VI 100/25mcg, with or without a long-acting muscarinic antagonist (LAMA), or to continue to receive usual care. FF/VI was ...